Acamprol: Clinically Proven Support for Alcohol Dependence Recovery
| Product dosage: 333 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.07 | $62.09 (0%) | 🛒 Add to cart |
| 60 | $1.89 | $124.18 $113.16 (9%) | 🛒 Add to cart |
| 90 | $1.42 | $186.27 $128.19 (31%) | 🛒 Add to cart |
| 120 | $1.19 | $248.36 $142.21 (43%) | 🛒 Add to cart |
| 180 | $1.05
Best per pill | $372.54 $188.27 (49%) | 🛒 Add to cart |
Synonyms | |||
Acamprol (acamprosate calcium) is a prescription medication specifically formulated to support long-term abstinence in individuals recovering from alcohol dependence. It works by helping to restore the natural balance of neurotransmitters in the brain, which are often disrupted by chronic alcohol use. By stabilizing chemical signaling, Acamprol reduces the physiological cravings and discomfort associated with alcohol withdrawal, thereby supporting sustained recovery efforts. This medication is most effective when used as part of a comprehensive treatment plan that includes counseling and psychosocial support.
Features
- Contains 333 mg of acamprosate calcium per delayed-release tablet
- Designed for oral administration, with a delayed-release formulation to optimize absorption
- Typically supplied in calendar blister packs to support adherence to the dosing schedule
- Manufactured under strict pharmaceutical quality control standards
- Prescription-only status ensures supervised use within a treatment plan
Benefits
- Reduces the physical craving for alcohol by acting on GABA and glutamate systems
- Supports long-term abstinence when combined with behavioral therapy
- Helps restore neurochemical balance disrupted by chronic alcohol consumption
- Does not cause sedation or intoxication, allowing for normal daily functioning
- Non-addictive profile with no abuse potential
- May improve sleep patterns and reduce anxiety associated with early recovery
Common use
Acamprol is indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. It is specifically designed for use in patients who are participating in a comprehensive management program that includes psychosocial support. The medication is intended to help manage the protracted withdrawal symptoms that can persist for weeks or months after alcohol cessation, reducing the risk of relapse during this vulnerable period. Treatment should be initiated as soon as possible after abstinence is achieved, following the acute withdrawal phase.
Dosage and direction
The recommended dosage of Acamprol for most patients is two 333 mg tablets taken three times daily (total daily dose 1998 mg). For patients with moderate renal impairment (creatinine clearance 30-50 mL/min), the dosage should be reduced to one 333 mg tablet three times daily. Tablets should be swallowed whole with water and not crushed or chewed. Acamprol can be taken with or without food, though consistent administration with meals may help establish a routine. Treatment duration is typically based on individual patient response, but continued use for up to one year has been shown to maintain treatment benefits.
Precautions
Patients should be monitored for the emergence of depression or suicidal thoughts, as these may occur during early recovery. Renal function should be assessed before initiation and periodically during treatment, particularly in older patients or those with conditions that may affect kidney function. Acamprol should be used with caution in patients with known hypersensitivity to any components of the formulation. Patients should continue to avoid alcohol consumption while taking Acamprol, as the medication is not intended to reduce the effects of acute alcohol consumption. Driving and operating machinery should be avoided until the patient’s individual response to treatment is established.
Contraindications
Acamprol is contraindicated in patients with severe renal impairment (creatinine clearance ≤30 mL/min). It should not be used in patients who have shown hypersensitivity to acamprosate calcium or any excipients in the formulation. The medication is not recommended for patients who continue to consume alcohol or who are in the acute withdrawal phase. Acamprol is contraindicated during pregnancy unless the potential benefit justifies the potential risk to the fetus, and should be used with caution in nursing mothers.
Possible side effects
The most commonly reported adverse reactions include diarrhea (occurring in approximately 10-15% of patients), nausea, abdominal pain, and pruritus. Other reported side effects may include headache, dizziness, insomnia, anxiety, and depression. These effects are generally mild to moderate in intensity and often diminish with continued treatment. Rare but serious side effects may include suicidal ideation, severe allergic reactions, and changes in kidney function. Patients should report any persistent or severe side effects to their healthcare provider promptly.
Drug interaction
Acamprol does not appear to interact significantly with the cytochrome P450 enzyme system and has shown minimal pharmacokinetic interactions with medications commonly used in alcohol dependence treatment, including disulfiram and naltrexone. However, caution should be exercised when combining Acamprol with other centrally acting medications. No clinically significant interactions have been observed with antidepressants, anxiolytics, or hypnotics, but additive effects on the central nervous system cannot be ruled out. Always inform your healthcare provider of all medications you are taking, including prescription, over-the-counter, and herbal products.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed one. Consistency in dosing is important for maintaining stable blood levels of the medication, so efforts should be made to adhere to the prescribed schedule. Setting reminders or using pill organizers can help maintain regular dosing.
Overdose
Cases of Acamprol overdose have been reported, with doses up to 56 grams resulting in diarrhea but no other serious clinical manifestations. In the event of suspected overdose, symptomatic and supportive treatment should be initiated. There is no specific antidote for acamprosate overdose. Gastrointestinal decontamination may be considered if ingestion occurred within a short time frame. Patients should be monitored for electrolyte imbalances due to potential diarrhea, and renal function should be assessed. Contact a poison control center or seek immediate medical attention for guidance.
Storage
Store Acamprol tablets at room temperature between 15°C and 30°C (59°F and 86°F). Keep the medication in its original container with the lid tightly closed to protect from moisture. Do not store in bathroom cabinets where humidity levels may fluctuate. Keep out of reach of children and pets. Properly discard any expired or unused medication according to local guidelines for pharmaceutical waste disposal. Do not flush medications down the toilet unless specifically instructed to do so.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Acamprol is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual results may vary, and the information provided here may not encompass all possible uses, directions, precautions, or adverse effects. Always consult with your healthcare provider before starting, stopping, or changing any medication regimen. The content does not replace professional medical judgment in any way.
Reviews
Clinical studies have demonstrated that Acamprol significantly improves abstinence rates compared to placebo when used as part of a comprehensive treatment program. In a 12-month study involving alcohol-dependent patients, those treated with Acamprol maintained complete abstinence for a median of 110 days compared to 65 days in the placebo group. Many patients report reduced alcohol cravings and improved ability to focus on recovery efforts. Healthcare providers note that the medication is particularly valuable for patients committed to abstinence who struggle with persistent physiological cravings. The delayed-release formulation is generally well-tolerated, with most adverse effects being gastrointestinal and typically transient. Patient satisfaction surveys indicate that those who adhere to the treatment regimen often report improved quality of life and better maintenance of sobriety.